Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 15/20 | 0.48 |
| ▸ | TYK2 | P29597 | 12/20 | 0.48 |
| ▸ | JAK2 | O60674 | 5/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | JAK3 | P52333 | 9/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27290131 | 0.92 | JAK1 (0.47) | JAK1TYK2JAK2KCNH2JAK3 | |
| SCHEMBL27295670 | 0.92 | TYK2 (0.48) | JAK1TYK2JAK2KCNH2AXL | |
| SCHEMBL30923150 | 0.92 | TYK2 (0.48) | JAK1TYK2JAK2KCNH2AXL | |
| SCHEMBL27289979 | 0.90 | TYK2 (0.48) | JAK1TYK2JAK2KCNH2JAK3 | |
| SCHEMBL27289981 | 0.89 | TYK2 (0.58) | JAK1TYK2JAK2KCNH2STAT3 | |
| SCHEMBL27414685 | 0.89 | JAK3 (0.61) | JAK1TYK2JAK2JAK3 | |
| SCHEMBL31711636 | 0.89 | JAK3 (0.61) | JAK1TYK2JAK2JAK3 | |
| SCHEMBL30923220 | 0.89 | JAK2 (0.48) | JAK1TYK2JAK2KCNH2AXL | |
| SCHEMBL27295711 | 0.89 | JAK2 (0.48) | JAK1TYK2JAK2KCNH2AXL | |
| SCHEMBL27290897 | 0.88 | EGFR (0.55) | JAK1TYK2JAK2KCNH2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024107658-A2 | INHIBITORS OF TYK2 | VYRNWY THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |